Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK256073 in Dyslipidemia
NCT00903617Phase 2Completed
- Sponsor
- GSK
- Start
- Jun 2009
- Primary completion
- Feb 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of GSK256073 in dyslipidemia (8 arms), sponsored by GSK. Primary endpoint: GSK256073 Area Under Concentration-time Curve (AUC) and High Density Lipoprotein Cholesterol (HDLc) Data to Evolve the Exposure-response Pharmacokinetic/Pharmacodynamic (PK/PD) Relationship for… at Week 8. Started Jun 2009; status: completed.
02
Drugs
GSK256073
03
Conditions
dyslipidemia
Beyond the preview
Go deeper on NCT00903617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00903617.